Hal Allergy

Focus: Hal Allergy is a Netherlands-based biotechnology company specializing in sublingual immunotherapy treatments for allergic diseases, including seasonal rhinitis, dust mite allergies, and food allergies. Founded in 2020 and publicly listed, the company operates a pipeline-focused model with multiple programs across clinical development stages.

Profile data last refreshed 4h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Hal Allergy

AI assessmentNot Hiring

No open roles listed right now. Follow Hal Allergy to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

HAL-MPE1

Peanut Allergy

PHASE_1

HAL-MPE1

Peanut Allergy

PHASE_1

HAL-MRE1

Rhinitis, Allergic

Help build intelligence for Hal Allergy

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused therapeutic area with clear clinical unmet need: 15 active clinical trials across allergy immunotherapy spanning Phase 1 through Phase 4, targeting high-prevalence indications like seasonal rhinitis and dust mite allergy.
European biotech base (Leiden, Netherlands) provides access to leading immunology research infrastructure and EU regulatory pathways with differentiated approval timelines versus US-centric competitors.
Diversified pipeline approach combining established PURETHAL and SUBLIVAC platforms with novel HAL candidates (HAL-MPE1 for peanut allergy, HAL-MRE1 for allergic rhinitis), offering multiple value inflection points.

Watch Out For

Early-stage company (founded 2020) with no disclosed employee count, revenue, funding, or cash position raises questions about operational scale, financial stability, and runway sustainability.
Currently zero active job postings despite public status suggests either minimal hiring or undisclosed recruitment challenges; limited visibility into organizational hiring trajectory or growth trajectory.

Generated by Claude from Hal Allergy's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

SUBLIVAC FIX Mite mixture

House Dust Mite Allergy

PHASE_1_2

sublingual immunotherapy

Seasonal Rhinitis and/or Rhinoconjunctivitis

PHASE_2

Placebo

Allergic Rhinitis

PHASE_2

SUBLIVAC FIX Phleum Prat.

Allergic Rhinitis

PHASE_2